FDA Fast-Tracks Verastem’s Breakthrough Oral Drug for KRAS G12D Lung Cancer
Verastem’s VS-7375 pill targets KRAS G12D lung cancer, a rare, hard-to-treat mutation with no approved drugs yet.
/ 3 items
#VSTM↓
Verastem Stops Lung Cancer Trial to Focus on More Promising Treatment
Verastem Oncology discontinues RAMP 203 trial for KRAS G12C lung cancer to prioritize VS-7375, showing 69% response rate in KRAS G12D patients.
Wall Street Analysts Issue Buy Ratings on Five Cancer Treatment Companies
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.